Background
Methods
Post-mortem brain tissue
Selection of typical and atypical AD cases
Typical NFT distribution n = 18 | Atypical NFT distribution n = 18 | |||
---|---|---|---|---|
Phenotype | Amnestic (n = 16) | Non-amnestic (n = 2) | Amnestic (n = 5) | Non-amnestic (n = 13) |
Male, n (%) | 6 (37) | 0 | 3 (60) | 8 (62) |
Age at death | 82 (± 7) | 88 (± 5) | 71 (± 11) | 67(± 7) |
Disease duration | 8 (± 5) | 7 (± 4) | 11 (± 5) | 8 (± 4) |
NFT stage [7] | ||||
n per stage 4/5/6 | 2/10/4 | 1/1/0 | 0/2/3 | 0/7/6 |
Amyloid stage [7] | ||||
n per stage O/A/B/C | 0/0/16 | 0/0/2 | 0/0/5 | 0/1/12 |
Case | Phenotype | Symptoms at clinical presentation | Sex | Age at death | Disease duration | NFT stage [7] | Amyloid stage [7] | Brain weight (grams) | Cause of death | PMI | ApoE |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Typical AD | Memory | F | 92 | 8 | 5 | C | 933 | Heart failure | 7:00 | 43 |
2 | Typical AD | Memory, disorientation | F | 84 | 4 | 4 | C | 908 | Cardiogenic shock | 4:15 | 32 |
3 | Typical AD | Memory, disorientation | F | 84 | 9 | 5 | C | 827 | Cachexia | 6:40 | 43 |
4 | Typical AD | Memory | F | 89 | 5 | 5 | C | 962 | Pneumonia | 6:28 | 43 |
5 | Typical AD | Memory | F | 83 | 6 | 6 | C | 1100 | Dehydration | 6:17 | 43 |
6 | Typical AD | Memory, behavior | F | 91 | 3 | 4 | C | 1026 | Cachexia | 6:25 | 33 |
7 | Typical AD | Memory, | F | 77 | 2 | 5 | C | 999 | Pneumonia | 6:05 | 33 |
8 | Typical AD | Memory, behavior | M | 70 | 2 | 6 | C | 1261 | Metastasized colon carcinoma | 6:20 | 43 |
9 | Typical AD | Memory | F | 76 | 12 | 5 | C | 1223 | Unknown | 10:45 | 44 |
10 | Typical AD | Memory | M | 60 | 2 | 6 | C | 1191 | Cachexia | 6:15 | 43 |
11 | Atypical AD | Aphasia, dyscalculia, agraphia, left-right agnosia, visuoconstruction problems | F | 65 | 6 | 6 | C | 975 | Pneumonia | 5:40 | 33 |
12 | Atypical AD | Aphasia, dyslexia, apraxia, visuoconstruction problems | M | 65 | 2 | 6 | C | 1057 | Cardiac insufficiency | 8:50 | 44 |
13 | Atypical AD | Aphasia, acalculia, fingeragnosia, apraxia | M | 64 | 7 | 5 | C | 1135 | Pneumonia | 4:45 | 42 |
14 | Atypical AD | Parkinsonism, falling, alien hand syndrome | F | 67 | 3 | 5 | C | 817 | Epileptic insult | 7:35 | 33 |
15 | Atypical AD | Aphasia, apathy, agitation | M | 59 | 6 | 6 | C | 1300 | Cachexia | 5:05 | 44 |
16 | Atypical AD | Aphasia, dyscalculia, dyslexia, disorientation | M | 62 | 3 | 6 | C | 1116 | Malign neuroleptic syndrome | 4:15 | 43 |
17 | Atypical AD | Aphasia, dyslexia, apathy, apraxia | M | 65 | 1 | 5 | C | 1150 | Euthanasia | 6:50 | 43 |
18 | Atypical AD | Aphasia, dyslexia, apraxia, visuospatial problems, behavior | M | 62 | 6 | 5 | B | 1153 | Cachexia | 4:40 | 33 |
19 | Atypical AD | Visual hallucinations, psychosis | M | 61 | 6 | 6 | C | 1355 | Pneumonia | 5:00 | 43 |
Immunohistochemistry (IHC)
Antibody | Antigen | Species | Origin details | Dilution | Incubation time | Antigen retrieval | Detection method |
---|---|---|---|---|---|---|---|
pTau, clone AT8 | Tau phosphorylated at Ser202 and Thr205 | Mouse IgG1 | ThermoFisher, Pittsburgh, USA | 1:10000 | 32 min at 36 °C | Heat-induced (pH 8.5) for 24 min | Optiview |
Amyloid-beta, clone IC-16 | N-terminus of amyloid-beta (aa 1-16) | Mouse IgG2a | Dr. Carsten Korth, University of Dusseldorf, Germany | 1:25 | 32 min at 36 °C | Heat-induced (pH 8.5) for 24 min | Optiview |
GFAP, clone EP672Y | Glial fibrillary acidic protein | Mouse | Roche, Basel, Switzerland | 1: 2 | 8 min at 37 °C | Heat-induced (pH 8.5) for 32 min | Optiview |
Iba1 | C-terminus of Iba1 | Rabbit | Wako Pure Chemical Industries, Osaka, Japan | 1:4000 | 32 min at 36 °C | Heat-induced (pH 8.5) for 16 min | Optiview |
CD68, clone KP1 | CD68 | Mouse IgG1 | Dako, Glostrup, Denmark | 1:1200 | Overnight at 4°C | Heat-induced (pH 6.0) by autoclave | EnVision |
HLA-DP/DQ/DR, clone CR3/43 | Alpha and beta-chains of all products of the DP, DQ, and DR subregions | Mouse IgG1 | Dako | 1:800 | Overnight at 4°C | Heat-induced (pH 6.0) by autoclave | EnVision |
C1q | C1q | Rabbit | Dako | 1:25600 | Overnight at 4°C | Heat-induced (pH 6.0) by autoclave | EnVision |
C3d | C3d | Rabbit | Dako | 1:3200 | Overnight at 4°C | Heat-induced (pH 6.0) by autoclave | EnVision |
C4b | C4b | Rabbit | Abcam, Cambridge, United Kingdom | 1:1600 | Overnight at 4°C | Heat-induced (pH 6.0) by autoclave | EnVision |
C5b-9, clone WU13-15 | Neoepitope on C9 in the membrane attack complex | Mouse | Hycult Biotech, Plymouth meeting, USA | 1:400 | Overnight at 4°C | Heat-induced (pH 6.0) by autoclave | EnVision |
Image analyses and quantitative assessment of immunostainings
Fluorescent triple stainings
Statistical analysis
Results
Atypical AD cases are younger than typical AD cases
Typical AD (n = 10) | Atypical AD (n = 9) | p-value | |
---|---|---|---|
Male, n | 2 | 7 | < .05 |
Age at death | 81 (± 10) | 63 (± 3) | < .01 |
Disease duration | 5 (± 3) | 4 (± 2) | .78 |
Brain weight (grams) | 1043 (± 146) | 1117 (± 161) | .32 |
PMI (h:min) | 6:19 (± 1:48) | 5:51 (± 1:33) | .66 |
NFT stage [7] n per stage 4/5/6 | 2/5/3 | 0/4/5 | .46 |
Amyloid stage [7] n per stage O/A/B/C | 0/0/10 | 0/1/8 | .47 |
ApoE genotype n per category 32/33/42/43/44 | 1/2/0/6/1 | 0/3/1/3/2 | .48 |
Distribution of pTau and amyloid-beta in typical and atypical AD
Transformed variable
|
Fixed Effect
|
Phenotype
|
Results for linear mixed model
| |
---|---|---|---|---|
Beta-coefficient
|
95% CI
| |||
pTau
|
Region x phenotype
|
1.53*
|
[1.33 – 1.72]
| |
Region
|
Typical AD
|
- 0.82*
|
[- 0.95 – - 0.68]
| |
Atypical AD
|
0.71*
|
[0.57 – 0.85]
| ||
Amyloid-beta
|
Region x phenotype
|
0.04
|
[- 0.06 – 0.15]
| |
Region
|
Both
|
- 0.46*
|
[- 0.54 – - 0.39]
| |
GFAP
|
Region x phenotype
|
1.25*
|
[1.02 – 1.48]
| |
Region
|
Typical AD
|
- 1.71*
|
[- 1.87 – - 1.56]
| |
Atypical AD
|
- 0.46*
|
[- 0.63 – - 0.29]
| ||
Iba1
|
Region x phenotype
|
0.10
|
[0.002 – 0.19]
| |
Region
|
Both
|
- 0.47*
|
[- 0.53 – - 0.41]
| |
CD68
|
Region x phenotype
|
- 0.43*
|
[0.38 – 0.48]
| |
Region
|
Typical AD
|
- 0.13*
|
[- 0.17 – - 0.10]
| |
Atypical AD
|
0.29*
|
[0.26 – 0.33]
| ||
HLA-DP/DQ/DR
|
Region x phenotype
|
0.97*
|
[0.88 – 1.06]
| |
Region
|
Typical AD
|
- 0.08*
|
[- 0.14 – - 0.03]
| |
Atypical AD
|
0.89*
|
[0.82 – 0.96]
| ||
C1q
|
Region x phenotype
|
- 0.05
|
[- 0.15 – 0.06]
| |
Region
|
Both
|
0.03
|
[- 0.05 – 0.10]
| |
C3d
|
Region x phenotype
|
0.74*
|
[0.62 – 0.86]
| |
Region
|
Typical AD
|
- 0.39*
|
[ - 0.47 – - 0.31]
| |
Atypical AD
|
0.36*
|
[0.26 – 0.45]
| ||
C4b
|
Region x phenotype
|
0.95*
|
[0.84 – 1.07]
| |
Region
|
Typical AD
|
- 0.24*
|
[- 0.32 – - 0.17]
| |
Atypical AD
|
0.71*
|
[0.62 – 0.80]
| ||
# of amyloid-beta plaques
|
Region x phenotype
|
0.58*
|
[0.41 – 0.75]
| |
Region
|
Typical AD
|
- 0.33*
|
[- 0.44 – - 0.21]
| |
Atypical AD
|
0.25*
|
[0.13 – 0.37]
| ||
# of C4b plaques
|
Region x phenotype
|
1.84*
|
[1.58 – 2.11]
| |
Region
|
Typical AD
|
- 0.39*
|
[- 0.56 – - 0.22]
| |
Atypical AD
|
1.46*
|
[1.25 – 1.66]
|